Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins.
Jini Kim, Seungkoo Lee, Young-Myeong Kim, Doo-Il Jeoung, Jongseon Choe
Index: Mol. Immunol. 55(3-4) , 418-23, (2013)
Full Text: HTML
Abstract
Evidence for the immunoregulatory function of lipid molecules in addition to proteins is accumulating. Based on our previous reports on the production of prostaglandin E₂ (PGE₂) and prostacyclin by human follicular dendritic cells (FDCs), we hypothesized that these prostaglandins (PGs) have a regulatory effect on the survival, proliferation, and differentiation of germinal center B (GC) cells. We observed that PGE₂ and a prostacyclin analog (beraprost) specifically enhanced the viable recovery of GC B cells in dose-dependent manners. FDC-like cells also mimicked the effect of PGE₂, which was significantly inhibited in the presence of indomethacin. The viable recovery was due to the prevention of cell death by PGE₂ and beraprost but did not result from augmented proliferation of GC B cells. The effect of PGE₂ and beraprost was manifest when they were added at early times of the culture. Interestingly, we found that the combined addition of a pan-caspase inhibitor and a necroptosis inhibitor gave rise to a similar result to PGE₂. Finally, PGE₂ and beraprost enhanced the generation of both CD20⁻CD38⁺ plasma cells and CD20⁺CD38⁻ memory B cells from GC B cells. Our current data suggest that FDCs play an important function of sustaining GC B cell survival by providing PGs. Our data also implies that selective cyclooxygenase inhibitors administered during infection or vaccination may have an adverse effect on the course of humoral immune response.Copyright © 2013 Elsevier Ltd. All rights reserved.
Related Compounds
Related Articles:
2015-03-01
[Br. J. Pharmacol. 172(5) , 1222-36, (2015)]
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.
2014-07-01
[Med. Chem. Res. 23(8) , 3836-3851, (2014)]
2014-11-01
[Cytotherapy 16(11) , 1486-500, (2014)]
2015-06-01
[Br. J. Pharmacol. 172 , 3028-42, (2015)]
2015-02-01
[J. Virol. 89(4) , 2268-86, (2015)]